General innate and adaptive immune system (None)

The general innate and adaptive immune system represents the body's collective defense mechanism against pathogens and internal threats like malignancy. The innate system serves as the first line of defense, utilizing physical barriers, phagocytic cells, and the complement system to provide rapid, non-specific responses (StatPearls, 2023). In contrast, the adaptive system involves B and T lymphocytes that recognize specific antigens, leading to a tailored response and the formation of immunological memory (NIH, 2023). While the system as a whole is not a single therapeutic target, its various components—including receptors like TLRs, cytokines like TNF-alpha, and checkpoints like PD-1—are critical focal points for drug development (Nature Reviews Drug Discovery, 2020). Therapeutic strategies often involve modulating these pathways to treat conditions ranging from autoimmune disorders and allergies to infectious diseases and cancer (Janeway's Immunobiology, 2017). Pharmacological intervention can either suppress an overactive immune response, as seen in rheumatoid arthritis, or stimulate a dormant one, as seen in oncology. The complexity of these interactions requires precise targeting to avoid systemic toxicity or secondary immunodeficiency. Monitoring the system's state is often achieved through various cellular and molecular biomarkers in clinical practice.

Other names

Immune systemHost defense systemInnate and adaptive immunity

Drugs targeting components of the immune system act through diverse mechanisms including immunosuppression (e.g., calcineurin inhibition), immunomodulation (e.g., cytokine neutralization), immunostimulation (e.g., checkpoint inhibition), and passive or active immunization (StatPearls, 2023; Nature Reviews Drug Discovery, 2020).